camp4 therapeutics corp - CAMP

CAMP

Close Chg Chg %
3.25 0.14 4.31%

Closed Market

3.39

+0.14 (4.31%)

Volume: 52.67K

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Company Overview: camp4 therapeutics corp - CAMP

CAMP Key Data

Open

$3.34

Day Range

3.14 - 3.43

52 Week Range

1.31 - 10.80

Market Cap

$152.36M

Shares Outstanding

46.88M

Public Float

18.23M

Beta

1.29

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.45

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

87.75K

 

CAMP Performance

1 Week
 
-10.79%
 
1 Month
 
-20.24%
 
3 Months
 
123.03%
 
1 Year
 
-56.59%
 
5 Years
 
N/A
 

CAMP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About camp4 therapeutics corp - CAMP

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP At a Glance

CAMP4 Therapeutics Corp.
1 Kendall Square
Cambridge, Massachusetts 02139
Phone 1-617-651-8867 Revenue 652.00K
Industry Biotechnology Net Income -51,791,000.00
Sector Health Technology 2024 Sales Growth 86.286%
Fiscal Year-end 12 / 2025 Employees 55
View SEC Filings

CAMP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 161.285
Price to Book Ratio 1.665
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.97
Enterprise Value to Sales 76.459
Total Debt to Enterprise Value 0.175

CAMP Efficiency

Revenue/Employee 11,854.545
Income Per Employee -941,654.545
Receivables Turnover 6.037
Total Asset Turnover 0.01

CAMP Liquidity

Current Ratio 6.916
Quick Ratio 6.916
Cash Ratio 6.672

CAMP Profitability

Gross Margin -160.123
Operating Margin -8,142.331
Pretax Margin -7,943.405
Net Margin -7,943.405
Return on Assets -77.733
Return on Equity -101.99
Return on Total Capital -72.055
Return on Invested Capital -89.415

CAMP Capital Structure

Total Debt to Total Equity 13.83
Total Debt to Total Capital 12.15
Total Debt to Total Assets 11.152
Long-Term Debt to Equity 8.81
Long-Term Debt to Total Capital 7.74
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Camp4 Therapeutics Corp - CAMP

Collapse All in section
All values USD millions. 2022 2023 2024 5-year trend
Sales/Revenue
- - 350.00K 652.00K
-
Sales Growth
- - - +86.29%
-
Cost of Goods Sold (COGS) incl D&A
- 947.00K 1.82M 1.70M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 947.00K 1.82M 1.70M
Depreciation
- 947.00K 1.82M 1.70M
Amortization of Intangibles
- - - -
-
COGS Growth
- - +92.61% -7.02%
-
Gross Income
- (947.00K) (1.47M) (1.04M)
Gross Income Growth
- - -55.65% +29.17%
-
Gross Profit Margin
- - -421.14% -160.12%
-
2022 2023 2024 5-year trend
SG&A Expense
- 44.05M 50.41M 52.04M
Research & Development
- 33.82M 38.79M 37.12M
Other SG&A
- 10.23M 11.61M 14.92M
SGA Growth
- - +14.42% +3.25%
-
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
- (45.00M) (51.88M) (53.09M)
Non Operating Income/Expense
- 809.00K 2.59M 1.30M
Non-Operating Interest Income
- 904.00K 2.81M 1.33M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
- (44.19M) (49.29M) (51.79M)
Pretax Income Growth
- - -11.54% -5.07%
-
Pretax Margin
- - -14,083.14% -7,943.40%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
- (44.19M) (49.29M) (51.79M)
Minority Interest Expense
- - - -
-
Net Income
- (44.19M) (49.29M) (51.79M)
Net Income Growth
- - -11.54% -5.07%
-
Net Margin Growth
- - -14,083.14% -7,943.40%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
- (44.19M) (49.29M) (51.79M)
Preferred Dividends
- - - -
-
Net Income Available to Common
- (44.19M) (49.29M) (51.79M)
EPS (Basic)
- -2.2657 -2.5271 -2.5709
EPS (Basic) Growth
- - -11.54% -1.73%
-
Basic Shares Outstanding
- 19.51M 19.51M 20.15M
EPS (Diluted)
- -2.2657 -2.5271 -2.5709
EPS (Diluted) Growth
- - -11.54% -1.73%
-
Diluted Shares Outstanding
- 19.51M 19.51M 20.15M
EBITDA
- (44.05M) (50.05M) (51.39M)
EBITDA Growth
- - -13.62% -2.67%
-
EBITDA Margin
- - -14,301.43% -7,882.21%
-

Snapshot

Average Recommendation BUY Average Target Price 10.39
Number of Ratings 6 Current Quarters Estimate -0.335
FY Report Date 12 / 2025 Current Year's Estimate -1.89
Last Quarter’s Earnings -0.55 Median PE on CY Estimate N/A
Year Ago Earnings -11.04 Next Fiscal Year Estimate -1.00
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 3 6 6
Mean Estimate -0.34 -0.29 -1.89 -1.00
High Estimates -0.26 -0.27 -1.59 -0.79
Low Estimate -0.56 -0.33 -2.31 -1.22
Coefficient of Variance -33.52 -10.39 -12.66 -14.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Camp4 Therapeutics Corp - CAMP

Date Name Shares Transaction Value
Apr 4, 2025 Yuri Maricich Chief Medical Officer 80,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Kelly Gold Chief Financial Officer 80,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Josh Mandel-Brehm Chief Executive Officer; Director 160,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 David Bumcrot Chief Scientific Officer 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Douglas E. Williams Director 17,787 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Murray Willis Stewart Director 17,787 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Camp4 Therapeutics Corp in the News